News of Note—VBI Vaccines, BiondVax and more

In this week's news of note, VBI Vaccines won FDA approval to start phase 3 testing on its hep B shot Sci-B-Vac, which is licensed in 15 countries.

> VBI Vaccines won FDA approval for its phase 3 program of hep B shot Sci-B-Vac. Enrollment is expected to start this year in the U.S., Europe and Canada. The vaccine is already licensed in Israel and 14 other countries. Release

> AMAL Therapeutics raised €8 million to advance its experimental colorectal cancer vaccine into human testing. Labiotech.eu story

> BiondVax, which is working on a universal flu vaccine candidate, voluntarily delisted from the Tel Aviv Stock Exchange. The company is still listed on Nasdaq. Release